A 73-year-old woman with stage 4 chronic kidney disease has a hemoglobin level of 7.9 g/dL. She asks whether she is a good candidate for erythropoietin-stimulating agent (ESA) therapy. Of the following, which is a true statement about erythropoietin and ESAs?
